Eisha Abid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eisha Abid has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Amna Amir Jalal
Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan
2 shared publications - Areeba Abid
Jinnah Sindh Medical University Karachi Pakistan
2 shared publications - Hiba Abid
Jinnah Sindh Medical University, V22W+F2H، Rafiqui H.J, Iqbal Shaheed Rd, Karachi Cantonment Karachi, Karachi City, Sindh 75510, Karachi, Pakistan
2 shared publications - Syed Ibad Hussain
Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan
2 shared publications - Umaima Parveen
Jinnah Sindh Medical University, Pakistan
2 shared publications Aamir Ahmed
Department of Medicine MTI Hayatabad Medical Complex Peshawar Pakistan
1 shared publication
Latest Publications
- 5 October 2026
- Published by Wiley in Head & Neck
- Vol. 48 (12) , 3501-3513
Efficacy and Safety of Cisplatin Versus Carboplatin for Patients With Squamous Cell Carcinoma of Head and Neck: A Systematic Review and Meta‐Analysis
Background: Cisplatin‐ and carboplatin‐based regimens are widely used in the treatment of head and neck squamous cell carcinoma (HNSCC), yet comparative evidence on survival and toxicity outcomes remains limited. While cisplatin is standard in many settings, carboplatin is often preferred in patients with comorbidities or impaired renal function. This systematic review and meta‐analysis aimed to synthesize available evidence comparing cisplatin versus carboplatin in HNSCC. Methods: A comprehensive literature search was conducted in PubMed, Embase, and the Cochrane Library from inception to February 2026. Randomized and observational studies comparing cisplatin‐ and carboplatin‐based regimens in HNSCC were included. Primary outcomes were overall survival (OS), progression‐free survival (PFS), locoregional recurrence‐free survival at 1, 3, and 5 years and distant metastasis‐free survival (DMFS) at 1 and 3 years. Secondary outcomes include grade ≥ 3 toxicities. Data were pooled using random‐effects meta‐analysis. Results: Eight studies comprising 1044 patients were included, including four recently published studies not previously pooled in head‐to‐head analyses. Pooled analyses showed no statistically significant differences between cisplatin and carboplatin in OS, PFS, LRRFS, or DMFS overall. Subgroup analyses across 1, 3, and 5‐year follow‐up intervals likewise demonstrated no significant differences for most outcomes. The only significant finding was a modest difference in 5‐year LRRFS favoring cisplatin, based on only two studies. No statistically significant differences were observed in grade ≥ 3 anemia, leukopenia, thrombocytopenia, or nausea/vomiting. Conclusions: Cisplatin and carboplatin‐based regimens yield largely comparable survival and toxicity outcomes in HNSCC. Treatment selection should be guided by patient comorbidities and tolerability.
- 5 October 2026
- Published by Wiley in Head & Neck
- Vol. 48 (12) , 3501-3513
Efficacy and Safety of Cisplatin Versus Carboplatin for Patients With Squamous Cell Carcinoma of Head and Neck: A Systematic Review and Meta‐Analysis
Background: Cisplatin‐ and carboplatin‐based regimens are widely used in the treatment of head and neck squamous cell carcinoma (HNSCC), yet comparative evidence on survival and toxicity outcomes remains limited. While cisplatin is standard in many settings, carboplatin is often preferred in patients with comorbidities or impaired renal function. This systematic review and meta‐analysis aimed to synthesize available evidence comparing cisplatin versus carboplatin in HNSCC. Methods: A comprehensive literature search was conducted in PubMed, Embase, and the Cochrane Library from inception to February 2026. Randomized and observational studies comparing cisplatin‐ and carboplatin‐based regimens in HNSCC were included. Primary outcomes were overall survival (OS), progression‐free survival (PFS), locoregional recurrence‐free survival at 1, 3, and 5 years and distant metastasis‐free survival (DMFS) at 1 and 3 years. Secondary outcomes include grade ≥ 3 toxicities. Data were pooled using random‐effects meta‐analysis. Results: Eight studies comprising 1044 patients were included, including four recently published studies not previously pooled in head‐to‐head analyses. Pooled analyses showed no statistically significant differences between cisplatin and carboplatin in OS, PFS, LRRFS, or DMFS overall. Subgroup analyses across 1, 3, and 5‐year follow‐up intervals likewise demonstrated no significant differences for most outcomes. The only significant finding was a modest difference in 5‐year LRRFS favoring cisplatin, based on only two studies. No statistically significant differences were observed in grade ≥ 3 anemia, leukopenia, thrombocytopenia, or nausea/vomiting. Conclusions: Cisplatin and carboplatin‐based regimens yield largely comparable survival and toxicity outcomes in HNSCC. Treatment selection should be guided by patient comorbidities and tolerability.
- 16 December 2025
- Published by Taylor & Francis in Future Oncology
- p. 1-17
Diagnostic accuracy and safety of image-guided transperineal versus transrectal prostate biopsy for clinically significant prostate cancer: a GRADE-assessed systematic review and meta-analysis
This systematic review and meta-analysis compared the diagnostic performance and complication profiles of transperineal biopsy (TPBx) versus transrectal biopsy (TRBx) for prostate cancer, incorporating recent randomized and large observational studies. Following PRISMA 2020 guidelines, PubMed, Scopus, Embase, and Cochrane Library were searched till April 2025. Studies directly comparing TPBx and TRBx were included. Risk of bias was assessed using RoB 2.0 for randomized trials and the Newcastle - Ottawa Scale for observational studies. Pooled relative risks (RRs) with 95% confidence intervals (CIs) were calculated using random-effects models. Subgroup analyses and a GRADE assessment were performed to evaluate the certainty of evidence. Twenty-nine studies (n = 90,621) were included. TPBx showed higher PCa detection (RR 1.08; 95% CI 1.01-1.15; p = 0.02) and csPCa detection (RR 1.14; 95% CI 1.05-1.24; p = 0.001), though the certainty of evidence was low to moderate. Heterogeneity was moderate to high. TPBx also showed lower infection-related complications and comparable overall events, though procedure-related pain was slightly higher. TPBx offers improved diagnostic yield and lower infection risk compared with TRBx, with comparable safety. However, given the moderate heterogeneity and limited high-quality RCTs, further confirmatory trials are necessary. https://www.crd.york.ac.uk/PROSPERO identifier is CRD420251035763.
- 16 December 2025
- Published by Taylor & Francis in Future Oncology
- p. 1-17
Diagnostic accuracy and safety of image-guided transperineal versus transrectal prostate biopsy for clinically significant prostate cancer: a GRADE-assessed systematic review and meta-analysis
This systematic review and meta-analysis compared the diagnostic performance and complication profiles of transperineal biopsy (TPBx) versus transrectal biopsy (TRBx) for prostate cancer, incorporating recent randomized and large observational studies. Following PRISMA 2020 guidelines, PubMed, Scopus, Embase, and Cochrane Library were searched till April 2025. Studies directly comparing TPBx and TRBx were included. Risk of bias was assessed using RoB 2.0 for randomized trials and the Newcastle - Ottawa Scale for observational studies. Pooled relative risks (RRs) with 95% confidence intervals (CIs) were calculated using random-effects models. Subgroup analyses and a GRADE assessment were performed to evaluate the certainty of evidence. Twenty-nine studies (n = 90,621) were included. TPBx showed higher PCa detection (RR 1.08; 95% CI 1.01-1.15; p = 0.02) and csPCa detection (RR 1.14; 95% CI 1.05-1.24; p = 0.001), though the certainty of evidence was low to moderate. Heterogeneity was moderate to high. TPBx also showed lower infection-related complications and comparable overall events, though procedure-related pain was slightly higher. TPBx offers improved diagnostic yield and lower infection risk compared with TRBx, with comparable safety. However, given the moderate heterogeneity and limited high-quality RCTs, further confirmatory trials are necessary. https://www.crd.york.ac.uk/PROSPERO identifier is CRD420251035763.
- Open Access
- 1 December 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 47 (4)
Comentário sobre “Associação entre o Kidney Donor Profile Index e os desfechos em um ano em receptores de transplante renal com doadores de critério padrão no Brasil”
- 1 December 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 47 (4)
Open AccessComentário sobre “Associação entre o Kidney Donor Profile Index e os desfechos em um ano em receptores de transplante renal com doadores de critério padrão no Brasil”
- Open Access
- 1 December 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 47 (4) , e20250255
Comment on “The association between the Kidney Donor Profile Index and one-year outcomes in Brazilian kidney transplant recipients of standard criteria donors”
- 1 December 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 47 (4) , e20250255
Open AccessComment on “The association between the Kidney Donor Profile Index and one-year outcomes in Brazilian kidney transplant recipients of standard criteria donors”
- 9 April 2025
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 40 (6) , 1631-1632
Strengthening Predictive Models and Risk Assessment in Autoimmune Gastritis: A Critical Appraisal
- 9 April 2025
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 40 (6) , 1631-1632
Strengthening Predictive Models and Risk Assessment in Autoimmune Gastritis: A Critical Appraisal
- Open Access
Comment on Aşır et al. Investigation of Vitamin D Levels in Men with Suspected Infertility. Life 2024, 14, 273
We have reviewed the article “Investigation of Vitamin D Levels in Men with Suspected Infertility” by Fırat Aşır
Open AccessComment on Aşır et al. Investigation of Vitamin D Levels in Men with Suspected Infertility. Life 2024, 14, 273
We have reviewed the article “Investigation of Vitamin D Levels in Men with Suspected Infertility” by Fırat Aşır